ABN AMRO Bank’s Ginkgo Bioworks DNA Stock Holding History

ABN AMRO Bank’s Portfolio DNA Stock Details DNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-5,016	Closed	-$67.6K	–	159
2024 Q2	$67.6K	Sell	5,016 -725	-13%	-$21.6K	﹤0.01%	153
2024 Q1	$266K	Sell	5,741 -292	-5%	-$15.1K	﹤0.01%	145
2023 Q4	$410K	Sell	6,033 -2,233	-27%	-$137K	0.01%	139
2023 Q3	$599K	Sell	8,266 -3,071	-27%	-$246K	0.01%	123
2023 Q2	$843K	Sell	11,337 -1,178	-9%	-$69.7K	0.02%	111
2023 Q1	$668K	Buy	+12,515	New	+$793K	0.01%	112

Other funds holding DNA

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACG

Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ABN AMRO Bank's DNA Position: Q3 2024 in Review

ABN AMRO Bank sold out of Ginkgo Bioworks (DNA) in Q3 2024, closing a stake of 5,016 shares — an estimated $67.6K sold.

ABN AMRO Bank first reported a position in DNA in Q1 2023 and held it in 6 quarters. The position peaked at $843K in Q2 2023. 159 funds tracked by Wall St. Rank hold DNA as of Q3 2024.

ABN AMRO Bank reported no remaining Ginkgo Bioworks position as of Q3 2024 after selling out during the quarter.
ABN AMRO Bank sold 5,016 Ginkgo Bioworks shares in Q3 2024, an estimated $67.6K.
ABN AMRO Bank first reported a position in Ginkgo Bioworks in Q1 2023 and held it in 6 quarters.
ABN AMRO Bank's Ginkgo Bioworks position peaked at $843K in Q2 2023.
159 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q3 2024.

Based on ABN AMRO Bank's 13F filing for Q3 2024, filed 28 Aug 2025.